Journal
PLATELETS
Volume 27, Issue 4, Pages 373-377Publisher
TAYLOR & FRANCIS INC
DOI: 10.3109/09537104.2015.1095874
Keywords
Platelet aggregation; prasugrel; ticagrelor; therapeutic window; variability
Categories
Funding
- Roche
- Austrian Society of Cardiology
- AstraZeneca
- Daiichi Sankyo
- Eli Lilly
- BMS/Sanofi Aventis
- Eli Lilly-Daiichi Sankyo
- AOPOrphan Pharmaceuticals
- Actelion
- Bayer
- Astra-Zeneca
- Servier
- Cordis
- Medtronic
- GSK
- Novartis
- Pfizer
- United Therapeutics
- Menarini
- Astra Zeneca
- Abbott
- Biotronik
- Amacord
- Edwards
Ask authors/readers for more resources
The aim of this study was to evaluate the distribution of platelet reactivity values in patients treated with prasugrel and ticagrelor. This prospective observational study enrolled 200 patients treated with prasugrel or ticagrelor. Platelet aggregation was determined by multiple electrode aggregometry after stimulation with adenosine diphosphate (ADP) in the maintenance phase of treatment with prasugrel or ticagrelor. Only 3% of patients in the prasugrel group and 2% of study participants in the ticagrelor group had high on treatment platelet reactivity (HTPR). The majority of patients displayed low on treatment platelet reactivity (LTPR; prasugrel: 69%; ticagrelor: 64%). The pharmacodynamic effect was similar in patients treated with prasugrel and ticagrelor: the median level of ADP-induced platelet aggregation was 15U (interquartile range IQR 9-21U) under prasugrel treatment and 17U (IQR 8-24U) under ticagrelor treatment (p=0.370). In conclusion, our study suggests that there is some degree of variability in ADP-induced platelet aggregation under treatment with prasugrel and ticagrelor.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available